Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its denosumab ...

Biliary tract cancer is increasing in incidence and mortality across Europe, with more people under the age of 60 years old ...

This contract has experienced an incredible rally since Jan. 22, however, the forward curve is pointing sharply downwards ...

A new global guideline for the diagnosis and treatment of Candida infections was recently published in Lancet Infectious ...

Researchers have suggested that uniform evidence standards and reporting requirements could help speed patient access to cell and gene therapies and help ensure consistent safety and efficacy ...

Continued strong commercial execution of the OGSIVEO launch in the U.S. with fourth quarter and full-year 2024 U.S. net product revenue for OGSIVEO of $61.5 million and $172.0 million, respectively.

Apellis (APLS) and Sobi announced the European Medicines Agency has validated an indication extension application for Aspaveli for the ...

C3i obtained a Drug Establishment License (DEL) to produce cell therapies for patients across Canada commercially.

C3i became the first contract development and manufacturing organization (CDMO) for cell and gene therapies in Canada to obtain a Drug Establishment License (DEL) to produce life-saving cell therapies ...

The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis' ...